Research News and Research

RSS

SOFAR licenses Immersion's TouchSense haptics technology for use in ALF-X telesurgical robot system

Immersion Corporation, the leading developer and licensor of haptics technology, today announced that SOFAR S.p.A., a leading Italian manufacturer of medical devices for minimally invasive surgery, has obtained a license to Immersion's TouchSense haptics technology for use in its ALF-X (Advanced Laparoscopy through Force Reflection) telesurgical robot system.

2 Jun 2010

Intimate partners can have important influence on another's substance use: Study

A new study of young people in the two years after high school finds that those in romantic relationships are less likely than their peers to report heavy drinking and marijuana use.

2 Jun 2010

Genes influence AIAA side effect in breast cancer survivors

Aromatase inhibitor-associated arthralgia (AIAA) is a major side effect in breast cancer survivors, producing joint pain so severe that as many as ten percent of women discontinue their therapy prematurely while undergoing treatment with these lifesaving drugs.

2 Jun 2010

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Ablexis, LLC, a biotechnology company dedicated to developing an innovative, next-generation platform for antibody drug discovery, announced today that it has completed a $12 million Series A financing. The round was led by Third Rock Ventures and included Pfizer Venture Investments. Proceeds from the financing will be used to continue advancing Ablexis' proprietary AlivaMab Mouse transgenic mouse platform for the discovery of human therapeutic antibodies.

2 Jun 2010

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

Alexion Pharmaceuticals, Inc. and Alexion Pharma International Sàrl today announced that the launch of Soliris (eculizumab) as a treatment for patients with PNH in Japan will begin in the third quarter of 2010, approximately three months earlier than previously expected.

2 Jun 2010

LAB Research's Canadian laboratory receives OECD-GLP compliance status

LAB Research Inc., a Canadian-based global non-clinical contract research organization, today announced that its Canadian laboratory has received a Good Laboratory Practices recognition from the Standards Council of Canada.

2 Jun 2010

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Two new studies suggest that excess levels of a protein associated with inflammation, TNF, may produce cognitive decline. TNF regulates both inflammation and brain function. TNF is elevated in the blood in many autoimmune diseases, and in the fluid surrounding the brain in Alzheimer's disease.

2 Jun 2010

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

G-coupled protein receptors (GPCRs), also known as 7-transmembrane proteins, constitute the single largest class of therapeutic targets for clinical and investigational drugs. There are ~800 predicted members of this class in the human genome, involved in diverse signaling pathways in a wide array of cells and tissue types. Modulation of GPCR function has proven to have therapeutic benefit in a wide variety of diseases in immunology, neurology, cardiology, and oncology.

2 Jun 2010

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

Geisinger Medical Center will participate in ProTECT III, a groundbreaking National Institute of Health -sponsored research study for the emergency treatment of traumatic brain injuries using the hormone progesterone.

2 Jun 2010

UCI study provides blueprint for enhanced treatment of inflammatory diseases

By discovering how adult neural stem cells navigate to injury sites in the central nervous system, UC Irvine researchers have helped solve a puzzle in the creation of stem cell-based treatments: How do these cells know where to go? Tom Lane and Kevin Carbajal of the Sue and Bill Gross Stem Cell Research Center found the answer with the body's immune system.

2 Jun 2010

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

LEO Pharma is in dialogue with the Greek authorities to find an alternative solution to withdrawing the company's pharmaceutical products from the Greek market.

2 Jun 2010

Synthetic peptide repairs, regenerates stroke-injured brain tissue

A synthetic version of a naturally occurring peptide promoted the creation of new blood vessels and repaired damaged nerve cells in lab animals, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.

2 Jun 2010

TQ can suppress growth of aggressive PCa cell lines: Researchers

Researchers at the Tulane University School of Medicine, in New Orleans, LA, have demonstrated that thymoquinone a major component of black seed oil (Nigella sativa) can suppress the growth of several aggressive prostate cancer cell lines, in vitro. Although previous studies have shown the anti-proliferative effects of TQ in different types of cancers, the molecular mechanism of this effect of TQ had not been delineated.

2 Jun 2010

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

The University of Minnesota and Mayo Clinic, under the mantle of the Minnesota Partnership for Biotechnology and Medical Genomics, have formed a strategic research relationship with the Karolinska Institute of Stockholm, Sweden, the top-rated medical research university in Europe. Leaders of each institution signed memoranda of understanding to commit to the formal ongoing collaboration, called the Frontiers of Biomedical Research.

2 Jun 2010

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

For those who suffer from balance disorders and loss of mobility, promising results from a new stabilizing device may help to reestablish mobility, confidence and independence. This week, Motion Therapeutics premieres its BalanceWear™ Stabilizing Garments at the 24th Annual Meeting for the Consortium of Multiple Sclerosis Centers in San Antonio.

2 Jun 2010

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Early trials using targeted monoclonal antibodies in combination with existing therapies show promise in treating pancreatic cancer and metastatic breast cancer, according to research that will be presented by investigators from the University of Pennsylvania's Abramson Cancer Center at the 2010 meeting of the American Society of Clinical Oncology June 4 through 8.

2 Jun 2010

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

Emerson Ecologics, LLC announces the debut of the first group of manufacturers to be awarded Partner status in the Emerson Quality Program(SM) (EQP). This one-of-a-kind quality assurance program for the nutritional supplements industry provides practitioners with manufacturer-specific quality and safety information to assist in confidently recommending the best products to patients.

2 Jun 2010

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

RepRegen™, the 'smart biomaterials' company previously known as BioCeramic Therapeutics, announced today that three-month data from an in vivo study of its StronBone™ bioactive glass with Strontium demonstrated that it can generate bone quality in and around defects that appears by analytical tests to be significantly superior to a standard bone void filler in the control defect.

2 Jun 2010

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Oncimmune LLC, maker of EarlyCDT-Lung, a simple blood test that aids physicians in risk assessment and the early detection of lung cancer, today announced validation study results demonstrating the diagnostic and economic benefits of a standardized and reproducible autoantibody laboratory test that may significantly improve the prognosis for lung cancer patients.

2 Jun 2010

Research News and Research

SOFAR licenses Immersion's TouchSense haptics technology for use in ALF-X telesurgical robot system

Intimate partners can have important influence on another's substance use: Study

Genes influence AIAA side effect in breast cancer survivors

Ablexis to advance transgenic mouse platform for antibody discovery with $12M Series A financing

Alexion Pharmaceuticals plans to launch Soliris in Japan for patients with PNH

LAB Research's Canadian laboratory receives OECD-GLP compliance status

Excess levels of a protein associated with TNF may produce cognitive decline: Studies

Roche, ATCC partner to research real-time endogenous GPCR function with xCELLigence System

GMC to participate in ProTECT III study of progesterone for emergency treatment of TBI

UCI study provides blueprint for enhanced treatment of inflammatory diseases

LEO Pharma to find alternative solution to withdraw pharmaceutical products from Greek market

Synthetic peptide repairs, regenerates stroke-injured brain tissue

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

TQ can suppress growth of aggressive PCa cell lines: Researchers

University of Minnesota, Mayo Clinic form strategic research relationship with Karolinska Institute

Motion Therapeutics to launch BalanceWear Stabilizing Garments for MS

Targeted monoclonal antibodies show promise for pancreatic and metastatic breast cancer

Emerson Ecologics announces awardees of Partner status in Emerson Quality Program

RepRegen reports 3-month data from study of StronBone bioactive glass with Strontium

Study demonstrates diagnostic, economic benefits of AABT for lung cancer patients

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest Life Science News